I’ve written in the past about the tendency of some researchers to compensate for weak study design or small sample size by over-hyping their research findings, particularly with the news media.
Several weeks ago, I wrote about the European Commission’s (EC) proposed scientific criteria to identify endocrine disrupting chemicals and highlighted what I, along with many others, believe are its numerous shortcomings.
On June 15 the EU Commission (EC) issued its highly anticipated “scientific criteria” for identifying Endocrine Disrupting Chemicals (EDCs). Now that the dust has settled, and stakeholders around the globe have had a chance to offer their thoughts, the time is ripe to explore to the heart of the criteria – what the EC selected (and what it didn’t select), and the potential impact their choices will have on consumers, industry and the global regulatory arena.
